Opinion/decision on a Paediatric investigation plan (PIP): Fasenra, Benralizumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Haematology-Hemostaseology, PIP number: P/0035/2022

EMEA-002229-PIP02-21

EMEA-002239-PIP02-21

Opinion/decision on a Paediatric investigation plan (PIP): Tavlesse, Fostamatinib, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Haematology-Hemostaseology;Immunology-Rheumatology-Transplantation, PIP number: P/0027/2022

Opinion/decision on a Paediatric investigation plan (PIP): Alecensa, Alectinib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Oncology, PIP number: P/0006/2022

Proline - Scientific guideline

EMEA-002839-PIP01-20-M01

EMEA-002700-PIP01-19-M01

Blenrep : EPAR - Public assessment report

Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, from 22 January 2024, 10:00 (CET) to 22 January 2024, 13:30 (CET)